GigCapital2, Inc. Adds Some Sugar to Sweeten their IPO
by Kristi Marvin on 2019-05-31 at 5:13pm

This afternoon, GigCapital2 (GIX.U), the second SPAC effort led by Avi Katz, re-filed their S-1 and amended their terms ahead of their expected IPO pricing next week.  Gig2, which is a $130 million TMT focused SPAC, has now added a Right to its Unit and reduced it’s life from 21 months to 18.

Looking more specifically at the changes, Gig2’s new Right is not the standard Right to receive 1/10th of one share, but rather it is 1/20th of one share. However, a right for 1/20th of share on a $130 million deal is rather small.  It’s value is only $6.5 million.  Will that be enough to satisfy investors?

Well, Gig2 has also reduced the duration on their SPAC by three months, down to 18 months total, to find and close an acquisition.  However, they have also added the Crescent Term for this go-around, which adjusts the warrant strike and redemption trigger in the event of the issuance of additional securities in connection with a business combination closing.  In light of Constellation Alpha’s recent announcement of their PIPE done at $3.25 per share for their business combination, the Crescent Term feels 100% necessary. It’s not even a sweetener, it just feels mandatory.  However, what Gig2 did do to sweeten it is change the threshold at which the Crescent Term kicks in.  The $9.20 threshold, which has become customary as of late, has now been given a little extra protective padding with a $9.50 threshold.

All told, Gig2 now has a lot of bells and whistles:  one full warrant, a 1/20th right, 18 months, the Crescent Term. And all those bells and whistles mean that investors have been pushing back on this SPAC in light of the fact that the Gig Team still needs to finish Gig1, which is asking for another six months to close their combination with Kaleyra.  Investors are not happy that this team is going to have a divided focus.  So, in order sell Gig2, this deal needed to be “sweetened-up”.  This SPAC will get done, but the real indicator of investor sentiment will be how it trades day-1.

Revised summary of terms below:

gig2 terms 5-31-19 v2

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved